Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$14.73 -0.7%	$16.64	$13.40 ▼ $20.68	$2.46B	0.54	1.85 million shs	957,583 shs
HCM HUTCHMED	$14.61 -7.2%	$14.94	$11.51 ▼ $21.92	$2.55B	0.66	106,959 shs	162,194 shs
MLTX MoonLake Immunotherapeutics	$39.42 -0.1%	$38.73	$31.42 ▼ $58.26	$2.52B	1.32	345,296 shs	334,612 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.01	N/A	N/A

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+1.21%	+0.68%	-13.33%	-20.57%	-10.61%
HCM HUTCHMED	+3.55%	+14.39%	+7.66%	+16.08%	-14.50%
MLTX MoonLake Immunotherapeutics	-0.15%	+2.92%	-0.55%	-13.68%	-7.02%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.0418 of 5 stars	4.3	1.0	0.0	0.0	2.9	4.2	2.5
HCM HUTCHMED	2.0761 of 5 stars	3.0	3.0	0.0	0.0	1.7	0.0	1.9
MLTX MoonLake Immunotherapeutics	2.1464 of 5 stars	3.5	2.0	0.0	0.0	2.7	2.5	0.0
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.50	Moderate Buy	$23.93	62.48% Upside
HCM HUTCHMED	2.00	Hold	$19.00	30.05% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$80.50	104.21% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SVA, MLTX, HCM, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/18/2025	MLTX MoonLake Immunotherapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$67.00
3/7/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$20.00 ➝ $20.00
2/27/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$28.00 ➝ $28.00
2/27/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
2/27/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
2/27/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$82.00 ➝ $73.00
2/27/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$62.00 ➝ $66.00
2/27/2025	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
2/11/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$22.00

(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	2.57	N/A	N/A	$2.63 per share	5.60
HCM HUTCHMED	$630.20M	4.04	$0.60 per share	24.51	$4.27 per share	3.42
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$8.15 per share	N/A
SVA Sinovac Biotech	$448.27M	1.44	$0.17 per share	38.95	$120.83 per share	0.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.36	18.88	19.38	N/A	13.83%	25.83%	14.71%	5/7/2025 (Estimated)
HCM HUTCHMED	$100.78M	N/A	0.00	10.01	N/A	N/A	N/A	N/A	5/9/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$36.01M	-$1.89	N/A	N/A	N/A	N/A	-15.54%	-15.09%	5/6/2025 (Estimated)
SVA Sinovac Biotech	-$99.92M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SVA, MLTX, HCM, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.05	N/A	N/A	N/A	$239.32 million	N/A
5/6/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	N/A	N/A	N/A	N/A	N/A
2/26/2025	Q4 2024	MLTX MoonLake Immunotherapeutics	-$0.63	-$0.72	-$0.09	-$0.72	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
HCM HUTCHMED	0.07	2.81	2.68
MLTX MoonLake Immunotherapeutics	N/A	25.51	25.51
SVA Sinovac Biotech	0.01	11.39	11.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
HCM HUTCHMED	8.82%
MLTX MoonLake Immunotherapeutics	93.85%
SVA Sinovac Biotech	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
HCM HUTCHMED	3.60%
MLTX MoonLake Immunotherapeutics	12.02%
SVA Sinovac Biotech	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	166.79 million	119.30 million	Optionable
HCM HUTCHMED	1,760	174.32 million	168.04 million	Not Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.22 million	Optionable
SVA Sinovac Biotech	3,261	99.64 million	86.89 million	Optionable

SVA, MLTX, HCM, and ACAD Headlines

Recent News About These Companies

Sinovac Biotech shareholder announces legal proceedings regarding board

April 24 at 7:56 PM | markets.businessinsider.com

Sinovac Not To Meet Annual Report Filing Deadline With SEC As Auditor Resigns; Calls For New Board

April 23 at 11:07 PM | nasdaq.com

Vivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board's Value Destructive Actions

April 23 at 10:05 PM | businesswire.com

SINOVAC Management Statement Regarding Auditor Resignation

April 22 at 12:06 AM | globenewswire.com

Sinovac Biotech Faces Audit Challenges Amid Board Legitimacy Issues

April 21, 2025 | tipranks.com

Heng Ren Urges Sinovac to Disclose Special Dividend Dates Proposes 41 Share Bonus Payout

April 11, 2025 | msn.com

Sinovac Biotech

April 11, 2025 | vir.com.vn

Heng Ren Urges Sinovac to Disclose Special Dividend Dates, Proposes $41/Share Bonus Payout

April 11, 2025 | vir.com.vn

Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the...

April 10, 2025 | macaubusiness.com

Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share

April 10, 2025 | prnewswire.com

Sinovac Biotech to declare $55.00 per share special cash dividend

April 2, 2025 | markets.businessinsider.com

SINOVAC Announces Decision to Declare Cash Dividend

April 1, 2025 | businesswire.com

SINOVAC Announces New Board Member and Chairman of the Audit Committee

March 28, 2025 | businesswire.com

Sinovac shareholder urges transparency over COVID windfall

March 24, 2025 | thepharmaletter.com

Heng Ren ‘demands’ Sinovac Biotech distribute $8.9B in cash to shareholders

March 21, 2025 | finance.yahoo.com

Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading

March 20, 2025 | prnewswire.com

Sinovac Biotech announces new board pursuant to privy council judgement

March 1, 2025 | markets.businessinsider.com

Sinovac Biotech Restructures Board Following Privy Council Ruling

February 28, 2025 | tipranks.com

SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order

February 28, 2025 | businesswire.com

Sinovac Biotech, Ltd. (SVA) stock forecast and price target

February 12, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA, MLTX, HCM, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$14.73 -0.10 (-0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$14.74 +0.01 (+0.07%)

As of 05:48 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

HUTCHMED NASDAQ:HCM

$14.61 -1.13 (-7.18%)

Closing price 04:00 PM Eastern

Extended Trading

$14.70 +0.09 (+0.62%)

As of 07:48 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

MoonLake Immunotherapeutics NASDAQ:MLTX

$39.42 -0.03 (-0.08%)

Closing price 04:00 PM Eastern

Extended Trading

$39.46 +0.03 (+0.09%)

As of 07:54 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time